| Form | Liquid |
|---|
| Host Species | Humanized |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG1-kappa |
|---|
| Purity | >95% as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 1 mg/ml |
|---|
| Endotoxin Level | Please contact with the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human |
|---|
| Target | CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | Q16552 |
|---|
| Background | Ixekizumab is a humanized monoclonal antibody to interleukin-17A which acts as an antiinflammatory agent and is used to treat moderate-to-severe plaque psoriasis. Ixekizumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury.<br>• The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781<br/>• Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability., PMID:26431948<br/>• IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment., PMID:37579542<br/>• The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases., PMID:34863654<br/>• IL-17 for therapy., PMID:28633806<br/>• Association Between., PMID:35271496<br/>• Vunakizumab: First Approval., PMID:39497021<br/>• The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies., PMID:31278139<br/>• IL-17A Modulates Peritoneal Macrophage Recruitment and M2 Polarization in Endometriosis., PMID:32117261<br/>• Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F., PMID:32973785<br/> |
|---|
| Alternative Names | RG4934, RO5310074, 1331830-76-2 |
|---|
| Species | Human |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|